
Gladstone Land Announces Preferred Stock Repurchase Authorization
"After a thorough analysis and in consultation with our board of directors, we are announcing another share repurchase authorization as part of a capital allocation strategy that we believe is in the best interest of our shareholders and our business. We believe that the current market conditions provide an attractive buying opportunity for our preferred stock and that using capital to repurchase our preferred shares at appropriate prices represents a favorable strategic use of capital," said David Gladstone, President of the Company.
About Gladstone Land Corporation:
Founded in 1997, Gladstone Land is a publicly traded real estate investment trust that acquires and owns farmland and farm-related properties located in major agricultural markets in the U.S. The Company currently owns 150 farms, comprised of approximately 103,000 acres in 15 different states and over 55,000 acre-feet of water assets in California. Gladstone Land's farms are predominantly located in regions where its tenants are able to grow fresh produce annual row crops, such as berries and vegetables, which are generally planted and harvested annually. The Company also owns farms growing permanent crops, such as almonds, blueberries, figs, olives, pistachios, and wine grapes, which are generally planted every 20-plus years and harvested annually. Over 30% of the Company's fresh produce acreage is either organic or in transition to become organic, and nearly 20% of its permanent crop acreage falls into this category. The Company may also acquire property related to farming, such as cooling facilities, processing buildings, packaging facilities, and distribution centers. Gladstone Land pays monthly distributions to its stockholders and has paid 149 consecutive monthly cash distributions on its common stock since its initial public offering in January 2013. The current per-share distribution on its common stock is $0.0467 per month, or $0.5604 per year. Additional information, including detailed information about each of the Company's farms, can be found at www.GladstoneLand.com.
Owners or brokers who have farmland for sale in the U.S. should contact:
Western U.S. - Bill Reiman at (805) 263-4778 or Bill.R@GladstoneLand.com;Mid-Atlantic and Midwest U.S. - Joey Van Wingerden at (703) 287-5914 or Joe.V@GladstoneLand.com; orSoutheastern U.S.- Brett Smith at (703) 287-5837 or Brett.S@GladstoneLand.com.
Lenders who are interested in providing Gladstone Land with long-term financing on farmland should contact Jay Beckhorn at (703) 587-5823 or Jay.Beckhorn@GladstoneCompanies.com.
For stockholder information on Gladstone Land, call (703) 287-5893. For Investor Relations inquiries related to any of the monthly dividend-paying Gladstone funds, please visit www.GladstoneCompanies.com.
CAUTION CONCERNING FORWARD-LOOKING STATEMENTS:
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements inherently involve certain risks and uncertainties, although they are based on the Company's current plans that are believed to be reasonable as of the date of this press release. Factors that may cause actual results to differ materially from these forward-looking statements include, but are not limited to, the Company's ability to procure financing for investments, downturns in the current economic environment, the performance of its tenants, the impact of competition on its efforts to renew existing leases or re-lease real property, and significant changes in interest rates. Additional factors that could cause actual results to differ materially from those stated or implied by its forward-looking statements are disclosed under the caption "Risk Factors" within the Company's Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on February 19, 2025, and certain other documents filed with the SEC from time to time. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
For further information: Gladstone Land, (703) 287-5893
SOURCE: Gladstone Land Corporation
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NVIDIA (NVDA) Announces Collaboration with Novo Nordisk
NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 Best Semiconductor Stocks to Buy According to Reddit. NVIDIA Corporation (NASDAQ:NVDA) announced a collaboration with Novo Nordisk to ramp up the drug discovery efforts via innovative AI use cases. The work supports Novo Nordisk's agreement with DCAI to utilise the Gefion sovereign AI supercomputer. The companies are focusing on creating customized AI models and agents that Novo Nordisk can utilise for early research and clinical development, as well as to apply advanced simulation and physical AI technologies. DCAI's Gefion supercomputer, which is powered by NVIDIA DGX SuperPOD™, offers Novo Nordisk an AI factory for running drug discovery and agentic AI workloads. A close-up of a colorful high-end graphics card being plugged in to a gaming computer. Elsewhere, Morningstar believes that NVIDIA Corporation (NASDAQ:NVDA)'s DC business has achieved exponential growth, increasing from $3 billion in fiscal 2020 to $115 billion in fiscal 2025. The firm opines that DC revenue remains supply-constrained, with near-term revenue expected to rise as more supply comes online. The firm assigned NVIDIA Corporation (NASDAQ:NVDA) a wide economic moat, stemming from the intangible assets related to its graphics processing units and switching costs associated with its proprietary software, like its CUDA platform for AI tools, which tends to enable developers to utilise Nvidia's GPUs to build AI models. Longriver Investment Partners released its Q2 2025 investor letter. Here is what the fund said: 'This shift in capex priorities has reopened the debate over compute architectures. Custom silicon promises a way out of NVIDIA Corporation's (NASDAQ:NVDA) pricing power, especially for inference. But the path is not straightforward. NVIDIA Corporation (NASDAQ:NVDA) is engaged in designing and selling semiconductor chips, mainly GPUs, which are important hardware components utilised in computing. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Mizuho Lifts PT on Broadcom (AVGO) Stock
Broadcom Inc. (NASDAQ:AVGO) is one of the 10 Best Semiconductor Stocks to Buy According to Reddit. Mizuho analyst Vijay Rakesh raised the price target on the company's stock to $315 from $310, while keeping an 'Outperform' rating. The firm increased estimates and price targets for several names in the broader semiconductors and semiconductor capital equipment group. The firm took a look at the data center and AI server market after the re-rating post the Liberation Day selloff. Overall, the firm expects Broadcom Inc. (NASDAQ:AVGO) to achieve industry-leading FY 2026 gross margins and operating margins, with potential FCF growth. A technician working at a magnified microscope, developing a new integrated circuit. In Q2 2025, Broadcom Inc. (NASDAQ:AVGO) achieved record revenue due to continued momentum in AI semiconductor solutions and VMware. Its Q2 2025 AI revenue saw an increase of 46% YoY to more than $4.4 billion, thanks to the strong demand for AI networking. Broadcom Inc. (NASDAQ:AVGO) expects growth in AI semiconductor revenue to accelerate to $5.1 billion in Q3 2025, delivering 10 consecutive quarters of growth, with the company's hyperscale partners continuing to invest. In Q2 2025, the company saw a record FCF of $6.4 billion, up 44% YoY. ClearBridge Investments, an investment management company, released its Q2 2025 investor letter. Here is what the fund said: 'Adding Broadcom Inc. (NASDAQ:AVGO), a leader in semiconductor design for communications and networking devices, enables the Strategy to better participate in the development of custom silicon chips for AI computing. Broadcom is well-positioned for continued healthy investment in AI, working with several large technology companies to develop custom silicon that we expect to grow alongside robust demand for Nvidia's all-purpose GPUs. The company's cloud infrastructure software business should also continue to grow for the next several years given its entrenched position within enterprises.' While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.